Monopar Therapeutics Inc. (NASDAQ:MNPR) CEO Sells $672,000.00 in Stock

Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) CEO Chandler Robinson sold 16,800 shares of the stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $40.00, for a total transaction of $672,000.00. Following the completion of the transaction, the chief executive officer directly owned 73,472 shares of the company's stock, valued at approximately $2,938,880. This trade represents a 18.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Monopar Therapeutics Stock Performance

NASDAQ MNPR traded up $1.31 during mid-day trading on Wednesday, reaching $41.07. 26,967 shares of the stock were exchanged, compared to its average volume of 362,258. Monopar Therapeutics Inc. has a 1-year low of $1.72 and a 1-year high of $54.30. The business's fifty day simple moving average is $35.63 and its 200 day simple moving average is $35.88. The stock has a market capitalization of $251.35 million, a PE ratio of -11.80 and a beta of 1.01.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.38) earnings per share for the quarter, beating analysts' consensus estimates of ($0.65) by $0.27. On average, analysts anticipate that Monopar Therapeutics Inc. will post -1.65 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on MNPR. Chardan Capital began coverage on shares of Monopar Therapeutics in a research note on Monday, June 23rd. They set a "buy" rating and a $60.00 price objective for the company. Cantor Fitzgerald began coverage on shares of Monopar Therapeutics in a research note on Monday, July 7th. They set an "overweight" rating and a $74.00 price objective for the company. HC Wainwright reissued a "buy" rating and set a $40.00 price objective on shares of Monopar Therapeutics in a research note on Tuesday, April 1st. Wall Street Zen raised shares of Monopar Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Finally, Jones Trading reissued a "hold" rating on shares of Monopar Therapeutics in a research note on Wednesday, April 2nd. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $60.00.

Hedge Funds Weigh In On Monopar Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in MNPR. JPMorgan Chase & Co. acquired a new position in shares of Monopar Therapeutics during the 4th quarter valued at $45,000. Geode Capital Management LLC lifted its holdings in shares of Monopar Therapeutics by 174.4% during the 4th quarter. Geode Capital Management LLC now owns 38,596 shares of the company's stock valued at $849,000 after acquiring an additional 24,530 shares in the last quarter. ADAR1 Capital Management LLC acquired a new position in shares of Monopar Therapeutics during the 4th quarter valued at $2,861,000. Adage Capital Partners GP L.L.C. acquired a new position in shares of Monopar Therapeutics during the 4th quarter valued at $13,182,000. Finally, RA Capital Management L.P. acquired a new position in shares of Monopar Therapeutics during the 4th quarter valued at $11,247,000. Institutional investors and hedge funds own 1.83% of the company's stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.